BLCM Bellicum Pharmaceuticals Inc.

2.02
-0.09  -4%
Previous Close 2.11
Open 2.14
Price To Book 1.82
Market Cap 92,938,313
Shares 46,009,066
Volume 538,132
Short Ratio
Av. Daily Volume 529,991

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 paediatric top-line data due 2Q 2019.
BPX-501 Rivo-cel
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1 initial data at ASCO June 1, 2019 noted 62/% SD rate.
BPX-601
Pancreatic cancer
Phase 2/3 ongoing.
Rivo-cel -THRIVE
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Latest News

  1. Does Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Have A High Beta?
  2. Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
  3. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm
  4. Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  5. Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
  6. (BLCM) Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged to Contact Firm
  7. Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
  8. Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  9. Bellicum Pharmaceuticals (BLCM) Reports Q1 Loss, Tops Revenue Estimates
  10. Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
  11. Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
  12. Edited Transcript of BLCM earnings conference call or presentation 12-Mar-19 9:00pm GMT
  13. Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018
  14. Bellicum Pharmaceuticals Q4 Earnings Preview
  15. Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call and Webcast on Tuesday, March 12, 2019
  16. Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Projections Moving into 2019
  17. How Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Could Add Value To Your Portfolio
  18. Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher
  19. Bellicum Pharmaceuticals Enters Oversold Territory
  20. Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA